Leukemia often results in severe anemia, which may significantly contribute to patient mortality and morbidity. However, the mechanisms underlying defective erythropoiesis in leukemia have not ...

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...

Prof. Jan Frayne’s group in the School of Biochemistry renowned for the creation of the Bristol Erythroid Line – Adult (BEL-A) immortalised cell line have expanded their portfolio and created a suite ...